Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
MINNEAPOLIS , April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, today released highlights from its business update
View HTML
Toggle Summary Precision Therapeutics Reports First Quarter 2018 Financial Results
MINNEAPOLIS , May 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three months ended March 31, 2018 and
View HTML
Toggle Summary Precision Therapeutics Reports Fiscal Year 2017 Financial Results
Company reports strengthening STREAMWAY® System sales and new strategic focus on the emerging precision medicine market MINNEAPOLIS , April 02, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying
View HTML
Toggle Summary Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation
MINNEAPOLIS , June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that it has signed a definitive merger agreement with
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery
MINNEAPOLIS , March 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with 48Hour Discovery (“48HD”) which grants it
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated
MINNEAPOLIS , March 21, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with CellBridge Incorporated (“CellBridge”)
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC
MINNEAPOLIS , March 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with SyntArray LLC .
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018
MINNEAPOLIS , March 26, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on May 15, 2018
MINNEAPOLIS , May 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML
Toggle Summary Precision Therapeutics, Formerly Skyline Medical, Announces Stock Ticker Symbol Change to AIPT View HTML